Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Autor: S. Ramalingam, J. Crawford, A. Chang, C. Manegold, R. Perez-Soler, J.-Y. Douillard, N. Thatcher, F. Barlesi, T. Owonikoko, Y. Wang, P. Pultar, J. Zhu, R. Malik, G. Giaccone, S. Della-Fiorentina, S. Begbie, R. Jennens, J. Dass, K. Pittman, N. Ivanova, T. Koynova, P. Petrov, A. Tomova, V. Tzekova, F. Couture, V. Hirsh, R. Burkes, R. Sangha, M. Ambrus, T. Janaskova, J. Musil, J. Novotny, P. Zatloukal, J. Jakesova, K. Klenha, J. Roubec, J. Vanasek, J. Fayette, J. Bennouna-Louridi, C. Chouaid, J. Mazières, H. Vallerand, G. Robinet, P.-J. Souquet, D. Spaeth, R. Schott, H. Lena, Y. Martinet, C. El Kouri, N. Baize, A. Scherpereel, O. Molinier, F. Fuchs, K.M. Josten, N. Marschner, F. Schneller, T. Overbeck, M. Thomas, J. von Pawel, M. Reck, W. Schuette, V. Hagen, C.-P. Schneider, V. Georgoulias, I. Varthalitis, K. Zarogoulidis, K. Syrigos, C. Papandreou, C. Bocskei, E. Csanky, E. Juhasz, G. Losonczy, Z. Mark, I. Molnar, Z. Papai-Szekely, S. Tehenes, I. Vinkler, S. Almel, A. Bakshi, S. Bondarde, A. Maru, A. Pathak, R.M. Pedapenki, K. Prasad, S.V.S.S. Prasad, N. Kilara, D. Gorijavolu, C.D. Deshmukh, S. John, L.M. Sharma, D. Amoroso, E. Bajetta, P. Bidoli, A. Bonetti, F. De Marinis, M. Maio, R. Passalacqua, S. Cascinu, A. Bearz, M. Bitina, A. Brize, G. Purkalne, M. Skrodele, A.A. Baba, K. Ratnavelu, M.H. Saw, M.C. Samson-Fernando, G.E. Ladrera, J. Jassem, P. Koralewski, P. Serwatowski, M. Krzakowski, C. Cebotaru, D. Filip, D.E. Ganea-Motan, C.H. Ianuli, I.G. Manolescu, A. Udrea, O. Burdaeva, M. Byakhov, A. Filippov, S. Lazarev, I. Mosin, S. Orlov, D. Udovitsa, A. Khorinko, S. Protsenko, H.L. Lim, Y.O. Tan, E.H. Tan, R. Bastus Piulats, J. Garcia-Foncillas, J. Valdivia, J. de Castro, M. Domine Gomez, S.W. Kim, J.-S. Lee, H.K. Kim, J.S. Lee, S.W. Shin, D.-W. Kim, Y.-C. Kim, K.C. Park, C.-S. Chang, G.-C. Chang, Y.-G. Goan, W.-C. Su, C.-M. Tsai, H.-P. Kuo, M. Benekli, G. Demir, E. Gokmen, A. Sevinc, M. Haigentz, M. Agarwal, S. Pandit, R. Araujo, N. Vrindavanam, P. Bonomi, A. Berg, J. Wade, R. Bloom, B. Amin, R. Camidge, D. Hill, M. Rarick, P. Flynn, L. Klein, K. Lo Russo, M. Neubauer, P. Richards, R. Ruxer, M. Savin, D. Weckstein, R. Rosenberg, T. Whittaker, D. Richards, W. Berry, C. Ottensmeier, A. Dangoor, N. Steele, Y. Summers, E. Rankin, K. Rowley, S. Giridharan, H. Kristeleit, C. Humber, P. Taylor

Publikováno v: Annals of Oncology. 24:2875-2880

Background Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). Patients and methods An FORTIS-M trial was an internat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279f128904fe8fc09b31972c2bf65519
https://doi.org/10.1093/annonc/mdt371

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome

Autor: George R. Blumenschein, Frances A. Shepherd, Jean Yves Douillard

Publikováno v: Chinese Journal of Lung Cancer, Vol 16, Iss 4, Pp C9-C20 (2013)

Introduction Non-small cell lung cancer (NSCLC) is often diagnosed in advanced stages and is associated with poor outcomes. Existing standards of care for NSCLC result in low overall cure rates, suggesting that novel treatment approaches are needed.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::090a2a4dd5a95a8fd481fbe678c3c15d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.